Disclosed is a patch comprising an adhesive layer on a backing layer, wherein the adhesive layer comprises lidocaine or a pharmaceutically acceptable salt thereof, propylene glycol, a rubber adhesive base and a terpene resin, wherein the content of the lidocaine or a pharmaceutically acceptable salt thereof in the adhesive layer in terms of free form is 2 mass% to 6 mass% with respect to the total mass of the adhesive layer, wherein the ratio of the mass of the lidocaine or a pharmaceutically acceptable salt thereof in terms of free form to the mass of propylene glycol in the adhesive layer is 1:0.6 to 1:1.8, and wherein the content of the terpene resin in the adhesive layer is 5 mass% to 18 mass% with respect to a total mass of the adhesive layer.

The invention provides compositions and methods for delivering vitamin D to a human subject. In one embodiment the invention provides a transdermal patch for the transdermal administration of vitamin D comprising: (a) a backing layer that serves as the outer surface of the patch during use; (b) an adhesive drug reservoir layer for affixing the patch to human skin; and (c) a release liner, which upon removal exposes the adhesive drug reservoir layer. The adhesive drug reservoir layer can include vitamin D, a polymeric adhesive, an organic solvent, and a permeation enhancer.

The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.

The invention relates to a system containing: a transdermal therapeutic system (TTS); a cylindrical separating layer having an outer periphery and an inner periphery; and a backing layer, which is applied to the cylindrical separating layer and protrudes beyond the cylindrical separating layer over the entire periphery. The invention further relates to a system for improving the adhesion of a TTS, to the use of the system, and to a kit containing the system.

The present invention relates to a transdermal therapeutic system (1) comprising an active-substance carrier layer (2) having at least one active-substance-containing polymer matrix (3) applied to the active-substance carrier layer (2), said matrix comprising at least one pressure-sensitive adhesive and at least one pharmacologically active substance absorbable through human or animal skin, and an adhesive carrier layer (6) coated as completely as possible with an active-substance-free pressure-sensitive adhesive (7), said adhesive carrier layer being bonded by means of the active-substance-free pressure-sensitive adhesive (7) directly to the flat side of the active-substance carrier layer (2) facing away from the active-substance-containing polymer matrix (3),
wherein the adhesive carrier layer (6) projecting circumferentially beyond the edge of the active-substance carrier layer (2), wherein the system is characterized in that between the active-substance-containing polymer matrix (3) and the active-substance-free pressure-sensitive adhesive (7) there is a circumferential zone (4) having a reduced thickness of coating with the active-substance-containing polymer matrix (3) and/or with the active-substance-free pressure-sensitive adhesive (7). The invention further relates to the use of this transdermal therapeutic system and to a kit that contains it.

Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

A portable surface acoustic wave (SAW)-generating system, a transdermal patch, and methods of treatment with improved transdermal administration of drugs are provided. Application of the transdermal patch comprising a therapeutically effective amount of the cannabis id, such as a cannabis drug, to the skin in combination with SAW results in a synergistic effect on delivery and absorption of the at least one drug as compared to topical administration of the drug via the transdermal patch without the surface acoustic waves generated by the portable SAW-generating system.

A method for suppressing a plasma concentration of an asenapine metabolite includes applying to a subject a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer includes asenapine and/or a pharmaceutically acceptable salt thereof, and an adhesive base agent.

The present invention provides a drug-loaded tissue adhesive film, comprising alternately superposed cationic layers and anionic layers, at least one of the cationic layers and the anionic layers being a drug layer, or at least one of the cationic layers and the anionic layers containing a drug with charges. The provided drug-loaded tissue adhesive film has good tissue adhesiveness, biocompatibility, degradable absorption, and stability, and the physical and chemical properties of the drug-loaded tissue adhesive film can be adjusted by adjusting material compositions.

The disclosure provides new medical device and manufacturing methods as well as chemicals that enhance delivery of pharmaceuticals from a transdermal patch, where the patch may include a film, adhesive, emulsifier, tackifier, or hydrogel.